• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BAYER PHARMA AG ESSURE; TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BAYER PHARMA AG ESSURE; TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE Back to Search Results
Model Number ESS305
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
Patient Problem Pain (1994)
Event Type  Injury  
Event Description
The below report was received by health authority ansm (reference number: (b)(4)) on 20-feb-2024.This spontaneous case was originally reported by a consumer and describes the occurrence of pelvic pain ("sharp pains") in an adult female patient who had essure inserted for female sterilisation.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.Essure was removed on (b)(6) 2014.On an unknown date, the patient had essure inserted.On unknown dates she experienced pelvic pain (seriousness criterion intervention required), urticaria ("hives"), heavy menstrual bleeding ("haemorrhagic periods"), bone pain ("pain in her bones"), arthralgia ("joints"), tooth disorder ("problems with her teeth"), visual impairment ("; problems with her vision"), dyspnoea ("shortness of breath"), chest pain ("painful feeling of pressure in her chest"), burnout syndrome ("burn out"), fatigue ("physical exhaustion") and emotional disorder ("emotional exhaustion").The patient was treated with surgery (essure removal :(b)(6) 2014).At the time of the report, the outcomes for pelvic pain, urticaria, heavy menstrual bleeding, bone pain, arthralgia, tooth disorder, visual impairment, dyspnoea, chest pain, burnout syndrome and fatigue were unknown.No causality assessment was received for essure with regard to pelvic pain, urticaria, heavy menstrual bleeding, bone pain, arthralgia, tooth disorder, visual impairment, dyspnoea, chest pain, burnout syndrome, fatigue or emotional disorder.The reporter commented: onset period january 2015.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 90 kg.Based on the available information, a review of our complaint records and other relevant data will be conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
 
Manufacturer Narrative
The below report was received by health authority ansm (reference number: (b)(4) on (b)(6) 2024.The most recent information was received on (b)(6) 2024.This spontaneous case was originally reported by a consumer and describes the occurrence of pelvic pain ("sharp pains") in an adult female patient who had essure inserted for female sterilisation.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On an unknown date, the patient had essure inserted.On unknown dates she experienced pelvic pain (seriousness criterion intervention required), urticaria ("hives"), heavy menstrual bleeding ("haemorrhagic periods"), bone pain ("pain in her bones"), arthralgia ("joints"), tooth disorder ("problems with her teeth"), visual impairment ("; problems with her vision"), dyspnoea ("shortness of breath"), chest pain ("painful feeling of pressure in her chest"), burnout syndrome ("burn out"), fatigue ("physical exhaustion") and emotional disorder ("emotional exhaustion").The patient was treated with surgery (essure removal).Essure was removed on (b)(6) 2014.At the time of the report, the outcomes for pelvic pain, urticaria, heavy menstrual bleeding, bone pain, arthralgia, tooth disorder, visual impairment, dyspnoea, chest pain, burnout syndrome and fatigue were unknown.No causality assessment was received for essure with regard to pelvic pain, urticaria, heavy menstrual bleeding, bone pain, arthralgia, tooth disorder, visual impairment, dyspnoea, chest pain, burnout syndrome, fatigue or emotional disorder.The reporter commented: onset period (b)(6) 2015.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 90 kg.Quality-safety evaluation of ptc: for essure: no defect could be confirmed by the manufacturer.All product batches have met the specifications regarding labeling, material, and process controls at time of release.Trend analyses of complaints are reviewed regularly, no signal was observed with regard to the reported complaint reason.The risk management file was reviewed and an update was not deemed required.A technical investigation of the complaint sample and batch record review could not be conducted, as no sample or batch number were available.The most recent follow-up information incorporated above includes data received on: 29-feb-2024: quality safety evaluation of ptc.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ESSURE
Type of Device
TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE
Manufacturer (Section D)
BAYER PHARMA AG
müllerstr. 178
berlin, 13353
GM  13353
Manufacturer (Section G)
BAYER PHARMA AG
müllerstr. 178
berlin, 13353
GM   13353
Manufacturer Contact
janice miller
100 bayer blvd.
p.o. box 915
whippany, NJ 07981
MDR Report Key18768743
MDR Text Key336123280
Report Number2951250-2024-00158
Device Sequence Number1
Product Code HHS
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
P020014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Consumer
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 03/01/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/23/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberESS305
Is the Reporter a Health Professional? No
Date Manufacturer Received02/29/2024
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient SexFemale
Patient Weight90 KG
-
-